Fig. 3
From: In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment
Comparative repeated dose PK profiles of PAT101 and rasburicase in SD rats. After weekly dosing of PAT101 or rasburicase for 4 weeks, plasma concentration versus time profiles were measured using enzyme activity assay at indicated time points (0.5, 1, 2, 4, and 8 hr after administration). Each test substance was injected at the same molar concentration of uricase. The calculated plasma uricase activity (mU/mL) in log scale was plotted against time (hr) to examine the PK profiles. Data are plotted as mean ± SD of 10 rats